Skip to main content
. Author manuscript; available in PMC: 2019 Mar 16.
Published in final edited form as: Pain. 2019 Mar;160(3):579–591. doi: 10.1097/j.pain.0000000000001438

Table 2.

OPPERA TMD genome-wide significant associations.

Group rsID Chr Position nearest genes EA EAF N OR SE P
all rs5862730 4 146211844 OTUD4, SMAD1 D 0.33 3030 1.42 0.06 2.82×10−8
fem rs5862730 4 146211844 OTUD4, SMAD1 D 0.33 1956 1.54 0.08 1.70×10−8
fem rs10092633 8 41123732 SFRP1 (intronic) A 0.03 1956 4.12 0.25 2.91×10−8
male rs34612513 3 137541085 SOX14, CLDN18* A 0.08 1074 3.00 0.19 1.49×10−8
male rs28865059 3 137687399 SOX14, CLDN18* C 0.09 1074 2.94 0.19 2.21×10−8
male rs13078961 3 137687685 SOX14, CLDN18* C 0.09 1074 2.94 0.19 2.22×10−8

rsID: SNP name; Chr: chromosome; EA: effect allele; EAF: effect allele frequency; N: number of subjects in analysis; OR: odds ratio; SE: standard error; P: P-value; D: deletion allele of an insertion/deletion polymorphism. Chromosome and position are from GRCh37/hg19 (build 37).

*

While we report the two genes flanking this intergenic locus, eQTL analysis indicated functional effects of the locus at the MRAS gene, located at 138,067,508–138,124,377 bp.